Teva Finland

What Teva Finland does

Teva Finland Oy is the Finnish operating subsidiary of Teva Pharmaceutical Industries Ltd., an Israeli-headquartered global pharmaceutical company publicly traded on the NYSE (TEVA). Incorporated in Finland as an Oy (public limited company under Finnish law) and headquartered in Espoo at Keilaranta 10, the entity distributes prescription pharmaceuticals, innovative medicines, and self-care products exclusively through licensed Finnish pharmacies. Its commercial motion is a hybrid of channel-partner distribution — via its Velox B2B extranet portal — and community-led engagement with healthcare professionals through expert-authored articles, downloadable patient materials, and sponsored participation in pharmacy and neurology congresses (Farmasian Päivät 2026 in Helsinki, EAN 2026 in Geneva).

The product portfolio spans three business lines: (1) generic medicines (rinnakkaislääkkeet), marketed under the global Teva franchise as the world's largest generic manufacturer; (2) innovative prescription medicines focused on two therapeutic areas — neurology (migraine, including content on CGRP monoclonal antibody treatments) and psychiatry (schizophrenia and serious mental health disorders); and (3) self-care / OTC products, with the consumer-facing Betolvex® line of Finnish-manufactured vegan B12 supplements (Betolvex® 1mg tablets in 50/100/150 packs, and Betolvex® Strong 1.25mg capsules in 30/90 packs) sold exclusively through pharmacies under the "vain apteekista" designation. The ratiopharm brand is co-marketed as a trusted pharmacy and consumer generic line.

The business model is wholesale-pharmaceutical distribution through licensed pharmacies, supplemented by healthcare-professional education and patient-facing content (migraine survival guides, headache diaries) in Finnish and Swedish. Customer segments are healthcare professionals (neurologists, psychiatrists, pharmacists) as the primary B2B audience and patients as the end consumer, with the entire addressable market confined to Finland. No financial figures — revenue, headcount, or funding — are disclosed for the Finnish entity; all capital allocation, M&A, and corporate strategy decisions flow from the publicly listed parent group.

Name

Teva Finland

Legal name

Teva Finland Oy

Website

https://tevafinland.fi

Company type

Private

Operating status

Operating

Short description

Teva Finland Oy is the Finnish subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), distributing generic medicines, innovative neurology and psychiatry treatments, and self-care products including the Betolvex® B12 line exclusively through licensed Finnish pharmacies.

Ownership category

akta.pro rank

Product category

Generic pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYCRADAGAM

Healthy Aging & Cognitive Support Supplements

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition

Keywords

• Generic pharmaceuticals
• Neurology treatments
• Psychiatric medicines
• OTC dietary supplements
• Pharmacy distribution

Headquarters

HQ city

Espoo

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals (Rinnakkaislääkkeet): Teva is described as the world's leading manufacturer of generic medicines (rinnakkaislääkkeet), providing affordable alternatives to branded medications through pharmacy distribution networks.
2. Innovative Medicines (Innovatiiviset lääkkeet): Teva develops and markets innovative prescription medicines, particularly in neurology and psychiatry therapeutic areas.
3. Self-care Products (Itsehoitovalmisteet): Over-the-counter products including Betolvex dietary supplements sold through pharmacies without prescription.
4. ratiopharm Brand: Trusted pharmacy and consumer brand for generic pharmaceutical products marketed in Finland.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Teva Finland Oy develops, markets, and supplies pharmaceutical and self-care products in Finland across three business lines: generic (rinnakkaislääke) prescription medicines, innovative prescription medicines concentrated in neurology (migraine) and psychiatry (schizophrenia, serious mental-health disorders), and over-the-counter self-care products including the Betolvex vegan B12-vitamin supplement line. All products are distributed exclusively through licensed Finnish pharmacies, and the company provides supporting healthcare-professional education and free downloadable patient resources (migraine survival guide, headache diary) in Finnish and Swedish.

Product overview

Teva Finland is the Finnish subsidiary of Teva Pharmaceutical Industries, operating across three core business lines: generic medicines (rinnakkaislääkkeet), innovative prescription medicines, and self-care (itsehoito) OTC products. Its therapeutic focus areas include neurology (migraine) and psychiatry (schizophrenia and serious mental disorders). The consumer-facing portfolio centers on the Betolvex® B12 vitamin line (Betolvex® 1mg and Betolvex® Strong 1,25 mg), both vegan and Finnish-manufactured dietary supplements sold in pharmacies. Supporting patient care, Teva Finland provides downloadable educational resources including the Migreenin selviytymisopas (Migraine Survival Guide) and Päänsärkypäiväkirja (Headache Diary), both available in Finnish and Swedish. The website itself functions as an informational and educational platform rather than a software product.

Differentiator

Problem solved

Functional benefit

Brands

• Betolvex: B12-vitamin supplement brand manufactured in Finland
• ratiopharm

Products and services

• Betolvex 1mg
• Betolvex Strong 1.25mg
• Generic (Rinnakkaislääkkeet) Prescription Medicines
• Innovative (Innovatiiviset) Prescription Medicines
• Self-care (Itsehoito) OTC Products

Quantifiable outcome

• CGRP antibody treatments reduce monthly migraine days by approximately 10 days with 6-month treatment in elderly patients over 65
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• ratiopharmcoreChannel Partner/ Reseller/ Distributorratiopharm is a trusted brand for pharmacies and consumers, marketed alongside Teva's own product portfolio in Finland. The brand is referenced as a reliable OTC and generic medicine option available through Finnish pharmacies.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• STADA: STADA specializes in generics, specialty pharmaceuticals, and consumer-health products sold through pharmacies. It is comparable to Teva Finland across generic medicines, OTC self-care, pharmacy channels, and branded consumer health.
• Sandoz: Sandoz is a global leader in generic and biosimilar medicines with broad pharmacy and institutional distribution. Its generic-led portfolio and focus on improving medicine affordability make it a direct product and business-model peer.
• Orifarm Group: Orifarm supplies generic, parallel-import, and OTC pharmaceutical products through European pharmacy and healthcare channels. It closely overlaps Teva Finland in affordable medicines, consumer self-care, and pharmacy distribution.
• Orion Pharma: Orion is a Finnish pharmaceutical company that develops, manufactures, and markets prescription and self-care medicines in Finland. Its domestic market presence, healthcare-professional relationships, and pharmacy-channel commercialization make it highly comparable to Teva Finland.
• Viatris: Viatris operates a global portfolio spanning branded and generic medicines and serves pharmacies, providers, and patients. Its combination of established medicines, generic exposure, and scaled commercialization is comparable to Teva Finland's broad pharmaceutical offering.
• KRKA: KRKA develops and manufactures prescription generics, OTC medicines, and self-medication products distributed through pharmacies. Its portfolio and distribution model closely resemble Teva Finland's generic, self-care, and pharmacy-led activities.

Broad incumbents

• Novartis: Novartis is a global innovative-medicines company with a meaningful neuroscience and migraine portfolio. It overlaps with Teva Finland's innovative neurology focus, prescribers, and pharmacy commercialization model, but spans a far wider set of therapeutic areas.
• AbbVie: AbbVie commercializes treatments in migraine and psychiatry to many of the same specialist prescribers and patient populations targeted by Teva Finland. It is an established incumbent in overlapping therapeutic categories but has a much broader global portfolio.
• Lundbeck: Lundbeck is an established neuroscience-focused pharmaceutical company serving neurologists, psychiatrists, and patients. It is a strong therapeutic peer to Teva Finland in migraine, psychiatry, and serious mental-health treatment, although it is more specialized in innovative CNS medicines.
• Pfizer: Pfizer is a global pharmaceutical company with migraine and broader neurological or psychiatric exposure. It competes for healthcare-professional engagement and prescription demand in overlapping therapeutic markets, while operating at substantially greater global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/TevaFinland
• LinkedInlinkedin.com/company/teva-finland

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Finland